Five Things You Should Know About NDMA Contamination in Valsartan
Numerous lots of the drug Valsartan have recently been recalled by the FDA due to NDMA contamination. Read below to learn what you should know about this contamination and FDA recall.
1. What is NDMA?
N-nitrosodimethylamine (NDMA) is a probable human carcinogen classified by the Environmental Protection Agency (EPA) as a semi-volatile organic chemical. Changes to the process used to manufacture Valsartan led to dangerous NDMA contamination of the drug.
2. Which Lots of Valsartan Were Recalled?
The list of Valsartan lots recalled due to dangerous NDMA contamination continues to grow. The FDA continues to update this list to reflect the specific lots included in the Valsartan recall.
3. What Types of Cancer Does Valsartan Cause?
NDMA may increase the risk of developing cancerous tumors. Research has shown that NDMA is linked to liver cancer, stomach cancer, colorectal cancer, intestinal cancer, esophageal cancer, prostate cancer, pancreatic cancer, non-hodgkin’s lymphoma, leukemia, and multiple myeloma.
4. Where Are the Drugs Coming From?
The NDMA-contaminated Valsartan was produced by three facilities: Zhejiang Huahai Pharmaceuticals in China, Hetero Labs Limited in India, and Zhejiang Tianyu in China.
5. What Should I Do Now?
If you or a loved one took Valsartan and was later diagnosed with cancer, contact GoldenbergLaw for a free consultation. We have over 30 years of experience in product liability litigation, and our attorneys hold several leadership positions in major drug and device lawsuits across the country. Call us. Leave the sleepless nights to us.